Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Astellas

Status: Terminated

Conditions: Chronic Lymphocytic Leukaemia (CLL); Indolent Non Hodgkin's Lymphoma (iNHL)

Study type: Observational

Funder types: Industry

Identifiers

NCT02273856

ONC-MA-1002

Details and patient eligibility

About

The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region. This study will also record encountered tumor subtype and stage and the instituted pharmacological treatments, as well as assess the clinical outcomes of treatments.

Full description

Patients will be followed up to 30 months.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent
• CLL patients or
• iNHL patients
• Clinical decision made to initiate or adapt treatment of CLL/iNHL("Need to treat")

Exclusion criteria

• Patient deemed unfit for enrollment by the documented opinion of the investigator
• Watch and wait patients
• Richter's transformation
• Patients otherwise not eligible for (pharmacological) intervention
• Moribund patients

Trial design

25 participants in 4 patient groups

Treatment naïve patients with CLL

Treatment naïve patients with iNHL

Relapsed/refractory patients with CLL

Relapsed/refractory patients with iNHL